Summit Financial, LLC Biomarin Pharmaceutical Inc Transaction History

Summit Financial, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	SELL	$83.81 - $99.0 $78,027 - $92,169	-931 Reduced 1.59%	57,628 $5.03 Million
Q4 2023 Feb 05, 2024	SELL	$76.22 - $98.51 $393,981 - $509,198	-5,169 Reduced 8.11%	58,559 $5.65 Million
Q3 2023 Nov 07, 2023	BUY	$85.07 - $94.48 $116,460 - $129,343	1,369 Added 2.2%	63,728 $5.64 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $5.41 Million - $6.25 Million	62,359 New	62,359 $5.41 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Summit Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Summit Financial, LLC with notifications on news.